Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade C 12.12 -1.62% -0.20
EPZM closed down 1.62 percent on Friday, May 17, 2019, on 72 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical EPZM trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Cup with Handle Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Crossed Above 20 DMA Bullish -1.62%
Morning Star Bullish -1.62%
Stochastic Buy Signal Bullish -1.62%
Cup with Handle Other -1.62%

Older signals for EPZM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biotechnology Life Sciences Cancers Leukemia Celgene Non Hodgkin Lymphoma Eisai Ezh2 Treatment Of Non Hodgkin Lymphoma
Is EPZM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 18.7
52 Week Low 5.14
Average Volume 688,926
200-Day Moving Average 10.1676
50-Day Moving Average 12.45
20-Day Moving Average 12.2255
10-Day Moving Average 12.038
Average True Range 0.581
ADX 16.4
+DI 19.986
-DI 19.8729
Chandelier Exit (Long, 3 ATRs ) 11.517
Chandelier Exit (Short, 3 ATRs ) 12.973
Upper Bollinger Band 12.9472
Lower Bollinger Band 11.5038
Percent B (%b) 0.43
BandWidth 11.80647
MACD Line -0.1819
MACD Signal Line -0.1579
MACD Histogram -0.024
Fundamentals Value
Market Cap 708.61 Million
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -5.86
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.74
Resistance 3 (R3) 12.79 12.65 12.63
Resistance 2 (R2) 12.65 12.49 12.62 12.60
Resistance 1 (R1) 12.38 12.39 12.31 12.33 12.56
Pivot Point 12.24 12.24 12.20 12.21 12.24
Support 1 (S1) 11.97 12.08 11.90 11.92 11.68
Support 2 (S2) 11.83 11.98 11.80 11.64
Support 3 (S3) 11.56 11.83 11.61
Support 4 (S4) 11.51